Key Insights

Highlights

Treatment Research

7 treatments under study, led by Pembrolizumab

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Phase 2 (1)

Trial Status

Unknown1

Clinical Trials (1)

Showing 1 of 1 trials
NCT05461235Phase 2Unknown

Anti-PD-1 Antibody Combined With Autologous DC and NK Cells in the Treatment of Digestive Carcinoma

Showing all 1 trials

Research Network

Common Treatments

  • Pembrolizumab1
  • Toripalimab1
  • Camrelizumab1
  • Tislelizumab1
  • Sintilimab1

Active Sponsors

  • China Medical University, China1

Top Investigators

Related Conditions

  • Gastrointestinal Tumours1
  • Dccell1
  • Pd1 Antibody1

Activity Timeline